Thymmune Acquisition Details Emerge: United Therapeutics to Pay Up to $300M
UTHR has more than doubled off its 52-week low of $272.12.
Summary
United Therapeutics is acquiring Thymmune Therapeutics for up to $300 million, comprising $140 million cash and up to $160 million in milestones. This strategic acquisition aims to advance iPSC-derived thymic therapy. While the headline also recaps Q1 financial results that missed estimates, those results were reported over two months ago. The financial terms of the Thymmune acquisition are new details, adding clarity to the company's pipeline expansion efforts.
At the time of this announcement, UTHR was trading at $553.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.6B. The 52-week trading range was $272.12 to $609.35. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.